Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx鈥檚 SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan鈥檚 AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX鈥檚 valuation.
Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you鈥檙e searching for 鈥淰olitionRx quarterly earnings report 10-Q filing鈥� or need 鈥淰olitionRx insider trading Form 4 transactions鈥� before market open, we have you covered. Key documents are mapped to the insights they contain:
- 10-K / annual report 鈥� cash-burn trends, patent status, and pipeline milestones in one 鈥淰olitionRx annual report 10-K simplified鈥� summary.
- 10-Q / quarterly earnings 鈥� segment spending, licensing revenue and trial enrollment metrics with concise 鈥淰olitionRx earnings report filing analysis鈥�.
- 8-K 鈥� real-time alerts on material events; think 鈥淰olitionRx 8-K material events explained鈥� minutes after filing.
- Form 4 鈥� 鈥淰olitionRx Form 4 insider transactions real-time鈥� so you can track executive stock moves the moment they file.
- DEF 14A proxy 鈥� drill into 鈥淰olitionRx proxy statement executive compensation鈥� without digging through appendices.
Use Stock Titan鈥檚 AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics鈥斺�渦nderstanding VolitionRx SEC documents with AI鈥� has never been easier. Schedule custom alerts, export tables for models and compare 鈥淰olitionRx executive stock transactions Form 4鈥� against peer trends, all from one screen.
VolitionRx held its Annual Meeting on June 18, 2025, where stockholders approved several significant proposals. The most notable change was the approval of a Certificate of Second Amendment to increase authorized shares from 175 million to 325 million shares of common stock ($0.001 par value).
Key meeting outcomes include:
- Election of eight board members, including CEO Cameron Reynolds, who received strong support with 36.1M votes
- Ratification of Sadler, Gibb & Associates as independent auditors with overwhelming approval (51.2M votes in favor)
- Approval of executive compensation through a non-binding advisory vote (34.4M votes in favor)
- Strong support for the share authorization increase with 49.4M votes in favor
The meeting had 51.6 million shares represented out of 100.7 million outstanding shares. The amendment became effective upon filing with Delaware's Secretary of State on June 18, 2025, marking a significant expansion in the company's potential capital structure.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
